Detecting Disease and Chemical signatures in Data
New Biological and Chemical data are reported on a daily basis. Combined with historical data and curated into massive, public and accessible databases is already having a significant impact over the way science is conducted; it is also beginning to affect drug discovery workflows. The ability to predict safety or efficacy from informatics-driven data mining has become one of the key objectives of drug and biomarker discovery. This emerging field has spawned a set of highly innovative approaches grouped under a new discipline that is called by some Network and others Systems Pharmacology. The drug discovery approach developed by MitoDys Therapeutics Ltd falls under this umbrella and derives from the ability to use chemogenomic datasets to translate disease-related differential expression profiles into prototype drugs. Furthermore, the nascent fields of Chemical Biology and Chemoinformatics have developed multiple tools and resources to generated predictive chemoproteomic signatures, disease and disease side-effect and gene associations and structure/sequence similarity approaches for the identification of drugs predicted to be effective in a selected disease setting.
MitoDys Therapeutics has assembled a group of world class scientists and neurodegenerative disease clinicians to assist it in developing a drug discovery workflow that takes advantage of available (as well as self-generated) data resources as well as state-of the art data processing tools. Its clinicians and biologists have also assisted it in defining the disease conditions most in need of a novel approach and where patient need is of the utmost urgency as well as the disease biology to target for drug discovery and development. This approach builds on the knowledge of multi-factorial disease biology that advances in molecular and cellular techniques and the inherent multi-interventional nature (eg polypharmacology) of most small molecules. Both of these feed into Mitodys's drug discovery platform to identify drugs who's actions are consistent with disease complexity. Furthermore, this approach is particularly well-suited to identifying drugs with existing safety profiles that can be repositioned to a new indication. The identification of commercially suitable repositioned drugs is a primary objective of the company as it enables reduced timelines to proof of concept clinical testing and potentially, a faster route to market. It is also well suited to seeking out combinations of existing drugs as well the identification of new chemical entities that can form the basis of polypharmacological optimisation.
MitoDys Therapeutics has assembled a group of world class scientists and neurodegenerative disease clinicians to assist it in developing a drug discovery workflow that takes advantage of available (as well as self-generated) data resources as well as state-of the art data processing tools. Its clinicians and biologists have also assisted it in defining the disease conditions most in need of a novel approach and where patient need is of the utmost urgency as well as the disease biology to target for drug discovery and development. This approach builds on the knowledge of multi-factorial disease biology that advances in molecular and cellular techniques and the inherent multi-interventional nature (eg polypharmacology) of most small molecules. Both of these feed into Mitodys's drug discovery platform to identify drugs who's actions are consistent with disease complexity. Furthermore, this approach is particularly well-suited to identifying drugs with existing safety profiles that can be repositioned to a new indication. The identification of commercially suitable repositioned drugs is a primary objective of the company as it enables reduced timelines to proof of concept clinical testing and potentially, a faster route to market. It is also well suited to seeking out combinations of existing drugs as well the identification of new chemical entities that can form the basis of polypharmacological optimisation.
